Institute for Systems Biology, Seattle, Washington, USA.
Molecular Engineering Sciences Institute, University of Washington, Seattle, Washington, USA.
mSystems. 2023 Feb 23;8(1):e0090422. doi: 10.1128/msystems.00904-22. Epub 2022 Dec 20.
There is an urgent need for strategies to discover secondary drugs to prevent or disrupt antimicrobial resistance (AMR), which is causing >700,000 deaths annually. Here, we demonstrate that tetracycline-resistant (Tet) Escherichia coli undergoes global transcriptional and metabolic remodeling, including downregulation of tricarboxylic acid cycle and disruption of redox homeostasis, to support consumption of the proton motive force for tetracycline efflux. Using a pooled genome-wide library of single-gene deletion strains, at least 308 genes, including four transcriptional regulators identified by our network analysis, were confirmed as essential for restoring the fitness of Tet E. coli during treatment with tetracycline. Targeted knockout of ArcA, identified by network analysis as a master regulator of this new compensatory physiological state, significantly compromised fitness of Tet E. coli during tetracycline treatment. A drug, sertraline, which generated a similar metabolome profile as the knockout strain, also resensitized Tet E. coli to tetracycline. We discovered that the potentiating effect of sertraline was eliminated upon knocking out , demonstrating that the mechanism of potential synergy was through action of sertraline on the tetracycline-induced ArcA network in the Tet strain. Our findings demonstrate that therapies that target mechanistic drivers of compensatory physiological states could resensitize AMR pathogens to lost antibiotics. Antimicrobial resistance (AMR) is projected to be the cause of >10 million deaths annually by 2050. While efforts to find new potent antibiotics are effective, they are expensive and outpaced by the rate at which new resistant strains emerge. There is desperate need for a rational approach to accelerate the discovery of drugs and drug combinations that effectively clear AMR pathogens and even prevent the emergence of new resistant strains. Using tetracycline-resistant (Tet) Escherichia coli, we demonstrate that gaining resistance is accompanied by loss of fitness, which is restored by compensatory physiological changes. We demonstrate that transcriptional regulators of the compensatory physiologic state are promising drug targets because their disruption increases the susceptibility of Tet E. coli to tetracycline. Thus, we describe a generalizable systems biology approach to identify new vulnerabilities within AMR strains to rationally accelerate the discovery of therapeutics that extend the life span of existing antibiotics.
目前迫切需要制定策略,发现能够预防或阻断抗菌药物耐药性(AMR)的二线药物,因为 AMR 每年导致超过 70 万人死亡。在这里,我们证明了耐四环素(Tet)的大肠杆菌经历了全局转录和代谢重塑,包括三羧酸循环的下调和氧化还原稳态的破坏,以支持质子动力用于四环素外排。使用四环素处理时,通过全基因组单基因缺失菌株的基因组文库,至少 308 个基因,包括我们的网络分析确定的四个转录调节因子,被确认为恢复 Tet E. coli 适应性所必需的。通过网络分析鉴定的 ArcA 的靶向敲除,作为这种新代偿生理状态的主调节因子,在四环素处理期间显著损害了 Tet E. coli 的适应性。网络分析鉴定的一种药物舍曲林(sertraline),其代谢组谱与缺失菌株相似,也使 Tet E. coli 对四环素重新敏感。我们发现,舍曲林的增效作用在敲除 时被消除,这表明潜在协同作用的机制是通过舍曲林在 Tet 菌株中四环素诱导的 ArcA 网络中的作用。我们的发现表明,针对代偿生理状态的机制驱动因素的治疗方法可以使 AMR 病原体对失去的抗生素重新敏感。到 2050 年,抗菌药物耐药性(AMR)预计将成为每年超过 1000 万人死亡的原因。虽然寻找新的强效抗生素的努力是有效的,但它们昂贵且赶不上新的耐药菌株出现的速度。迫切需要一种合理的方法来加速发现能够有效清除 AMR 病原体甚至预防新的耐药菌株出现的药物和药物组合。使用耐四环素(Tet)的大肠杆菌,我们证明获得耐药性伴随着适应性的丧失,这种丧失通过代偿性生理变化得到恢复。我们证明,代偿生理状态的转录调节因子是有前途的药物靶点,因为它们的破坏增加了 Tet E. coli 对四环素的敏感性。因此,我们描述了一种可推广的系统生物学方法,以确定 AMR 菌株中的新弱点,从而合理地加速发现延长现有抗生素寿命的治疗方法。